Zoetis launches CircoMax Myco to deliver broader coverage against PCV2 - Veterinary Practice
Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×

Zoetis launches CircoMax Myco to deliver broader coverage against PCV2

This is the first vaccine that includes two PCV2 genotypes (a and b), and an innovative M. hyopneumoniae fraction, in a single-dose formulation

Zoetis today
announced the launch of CircoMax Myco, in the European
Union. It is the first, and only, vaccine that
includes two porcine circovirus type 2 (PCV2) genotypes (a and b),
providing broader coverage against PCV2 and longest-lasting combined protection
against two of the main pathogens in the global
pig industry, PCV2 and Mycoplasma
hyopneumoniae
.

The new product is designed to stimulate both cell-mediated and antibody-based
immunity, providing a broad immune response that mimics a natural infection.
CircoMax Myco has demonstrated robust performance in field
conditions, delivering improvements in average daily gain (ADG) and close-out
weights versus negative controls, helping producers get more kilograms of pork
to market.

CircoMax Myco comes in an easy to administer, ready to use
single-dose combination with a duration of immunity (DOI) of 23 weeks against
both PCV2 and M. hyopneumoniae. It is made with the
MetaStim adjuvant and has a demonstrated safety profile as
described in the summary of product’s characteristics (SPC).

“The swine industry needs to adapt to evolving challenges and our research has
consistently demonstrated that with its unique technology CircoMax Myco offers robust protection against
PCV2 and M. hyopneumoniae.
It also shows that this new product offers the best chance at protection
against continuously evolving PCV2 genotypes – providing a broader umbrella for
pig health and productivity,” said Alvaro Aldaz, Director, Global Commercial
Development, Swine, Zoetis. “Analysis of new European PCV2 strains isolated in
multiple countries confirm that CircoMax Myco offers broader
coverage than competitor vaccines based on PCV2a only.”

Monica Balasch, Director, Global Biologicals, Zoetis, said: “We believe that we
need to be able to adapt to, and stay one step ahead of, evolving PCV2
genotypes. Our new vaccine, CircoMax Myco, offers high levels of
efficacy, convenience and proven safety. This piglet vaccine, similar to
other Zoetis products such as Suvaxyn PRRS MLV, will offer a robust
long-lasting protection for healthy piglets against advancing threats.”

Veterinary Practice

Veterinary Practice is an online knowledge and information hub for veterinary professionals across all specialties. It provides reliable, useful and interesting content, written by expert authors and covering small animal, large animal, equine and practice management sectors of the veterinary surgeon and nursing professions.


More from this author

Have you heard about our
IVP Membership?

A wide range of veterinary CPD and resources by leading veterinary professionals.

Stress-free CPD tracking and certification, you’ll wonder how you coped without it.

Discover more